DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc today announced its second quarter 2008 financial results and provided a business update. Commenting on Elan’s business, Kelly Martin, Elan’s president and chief executive officer, said, “Disciplined execution and tangible results for the benefit of patients and shareholders continue to be our enduring tenet. We are encouraged by the recently reported top-line results from our Phase 2 trial of bapineuzumab which provides further validation of our approach. We look forward to sharing the full clinical data later this month. In addition, we are pleased to celebrate the second anniversary of Tysabri in MS and the launch of Tysabri for Crohn’s patients. We will continue to demonstrate focused and disciplined leadership that will provide continuous progress that ultimately leads to benefits for our shareholders, patients, and their caregivers.”
